-
1.发明授权公开(公告)号：US07378095B2
公开(公告)日：2008-05-27
申请号：US11193746
申请日：2005-07-29
CPC分类号： A61K38/179 , A61K38/28 , A61K48/00 , C12N15/1136 , C12N2310/11 , C12N2310/14 , A61K2300/00
摘要： Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.
摘要翻译： 通过阻断或抑制VEGF介导的活性来治疗哺乳动物，特别是人类的糖尿病的方法。 VEGF介导的活性的优选抑制剂是VEGF拮抗剂，例如能够结合和阻断VEGF的SEQ ID NO：2的VEGF融合蛋白捕获物。 本发明的方法可以与其它疗法组合，例如用胰岛素治疗。
-
2.发明授权Modified ciliary neurotrophic factor, method of making and methods of use thereof 有权修饰的睫状神经营养因子，制备方法及其使用方法公开(公告)号：US06680291B1
公开(公告)日：2004-01-20
申请号：US09454380
申请日：1999-12-03
IPC分类号： A61K3800
CPC分类号： C07K14/475 , A61K38/00
摘要： Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or non insulin-dependent diabetes mellitus.
摘要翻译： 改良的睫状神经营养因子，生产方法和使用方法，特别是治疗亨廷顿氏病，肥胖症和妊娠或非胰岛素依赖性糖尿病。
-
公开(公告)号：US07052691B2
公开(公告)日：2006-05-30
申请号：US10811170
申请日：2004-03-26
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/30
摘要： Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as a VEGF trap capable of binding and blocking VEGF.
摘要翻译： 通过阻断或抑制VEGF介导的活性来治疗哺乳动物，特别是人类的糖尿病的方法。 VEGF介导的活性的优选抑制剂是VEGF拮抗剂，例如能够结合和阻断VEGF的VEGF陷阱。
-
公开(公告)号：US09018356B2
公开(公告)日：2015-04-28
申请号：US13517662
申请日：2012-06-14
CPC分类号： C07K16/22 , A61K31/455 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
摘要翻译： 提供了特异性结合并抑制或干扰人类血管生成素样蛋白3（hANGPTL3）的至少一种活性的人抗体的完全人抗体或抗原结合片段。 人抗hANGPTL3抗体可用于治疗与ANGPTL3相关的疾病或病症，例如高脂血症，高脂蛋白血症和血脂异常，包括高甘油三酯血症，高胆固醇血症，乳糜微血症等。 此外，可以将抗hANGPTL3抗体施用于有需要的受试者，以预防或治疗脂代谢异常是危险因素的疾病或病症。 这些疾病或病症包括心血管疾病，例如动脉粥样硬化和冠状动脉疾病; 急性胰腺炎 非酒精性脂肪性肝炎（NASH）; 糖尿病; 肥胖; 等等。
-
公开(公告)号：US20100166768A1
公开(公告)日：2010-07-01
申请号：US12637942
申请日：2009-12-15
IPC分类号： A61K39/395 , C07K16/40 , C07H21/04 , C12N15/63 , C12P21/06
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12Y304/21061
摘要： An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
摘要翻译： 特异性结合并抑制人前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（hPCSK9）的人抗体的人抗体或抗原结合片段，其特征在于能够在24,60或90天将血清LDL胆固醇降低40-80％ 相对于前期水平，血清HDL胆固醇几乎没有或没有降低和/或通过ALT和AST测量确定对肝功能具有很小或没有可测量的影响。
-
公开(公告)号：US08357371B2
公开(公告)日：2013-01-22
申请号：US13095234
申请日：2011-04-27
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
CPC分类号： C07K16/40 , A61K31/40 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
摘要翻译： 本发明提供治疗高胆固醇血症的方法。 本发明的方法包括向有需要的受试者施用包含抗PCSK9抗体或其抗原结合片段的治疗组合物。
-
公开(公告)号：US08354103B2
公开(公告)日：2013-01-15
申请号：US12977361
申请日：2010-12-23
申请人： Mark W. Sleeman , Viktoria Gusarova , Jee H. Kim , Gang Chen
发明人： Mark W. Sleeman , Viktoria Gusarova , Jee H. Kim , Gang Chen
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/26 , A61K31/216 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/567 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
-
公开(公告)号：US08062640B2
公开(公告)日：2011-11-22
申请号：US12637942
申请日：2009-12-15
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12Y304/21061
摘要： An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
摘要翻译： 特异性结合并抑制人前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（hPCSK9）的人抗体的人抗体或抗原结合片段，其特征在于能够在24,60或90天将血清LDL胆固醇降低40-80％ 相对于前期水平，血清HDL胆固醇几乎没有或没有降低和/或通过ALT和AST测量确定对肝功能具有很小或没有可测量的影响。
-
公开(公告)号：US08501184B2
公开(公告)日：2013-08-06
申请号：US12949846
申请日：2010-11-19
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12Y304/21061
摘要： An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
摘要翻译： 特异性结合并抑制人前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（hPCSK9）的人抗体的人抗体或抗原结合片段，其特征在于能够在24,60或90天将血清LDL胆固醇降低40-80％ 相对于前期水平，血清HDL胆固醇几乎没有或没有降低和/或通过ALT和AST测量确定对肝功能具有很小或没有可测量的影响。
-
公开(公告)号：US20130171149A1
公开(公告)日：2013-07-04
申请号：US13517662
申请日：2012-06-14
IPC分类号： C07K16/22 , A61K45/06 , A61K39/395
CPC分类号： C07K16/22 , A61K31/455 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.034 秒)